CODEXIS INC (CDXS) Stock Fundamental Analysis

NASDAQ:CDXS • US1920051067

1.2 USD
+0.02 (+1.69%)
At close: Feb 13, 2026
1.2 USD
0 (0%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall CDXS gets a fundamental rating of 2 out of 10. We evaluated CDXS against 58 industry peers in the Life Sciences Tools & Services industry. CDXS has a bad profitability rating. Also its financial health evaluation is rather negative. CDXS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CDXS had negative earnings in the past year.
  • CDXS had a negative operating cash flow in the past year.
  • In the past 5 years CDXS always reported negative net income.
  • In the past 5 years CDXS reported 4 times negative operating cash flow.
CDXS Yearly Net Income VS EBIT VS OCF VS FCFCDXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -51.59%, CDXS is not doing good in the industry: 84.48% of the companies in the same industry are doing better.
  • CDXS has a worse Return On Equity (-165.92%) than 82.76% of its industry peers.
Industry RankSector Rank
ROA -51.59%
ROE -165.92%
ROIC N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
CDXS Yearly ROA, ROE, ROICCDXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • With an excellent Gross Margin value of 79.31%, CDXS belongs to the best of the industry, outperforming 98.28% of the companies in the same industry.
  • CDXS's Gross Margin has been stable in the last couple of years.
  • CDXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
CDXS Yearly Profit, Operating, Gross MarginsCDXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CDXS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CDXS has more shares outstanding
  • The debt/assets ratio for CDXS is higher compared to a year ago.
CDXS Yearly Shares OutstandingCDXS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CDXS Yearly Total Debt VS Total AssetsCDXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -6.80, we must say that CDXS is in the distress zone and has some risk of bankruptcy.
  • CDXS's Altman-Z score of -6.80 is on the low side compared to the rest of the industry. CDXS is outperformed by 84.48% of its industry peers.
  • A Debt/Equity ratio of 1.03 is on the high side and indicates that CDXS has dependencies on debt financing.
  • CDXS's Debt to Equity ratio of 1.03 is on the low side compared to the rest of the industry. CDXS is outperformed by 81.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -6.8
ROIC/WACCN/A
WACC11.83%
CDXS Yearly LT Debt VS Equity VS FCFCDXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • CDXS has a Current Ratio of 4.12. This indicates that CDXS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 4.12, CDXS is doing good in the industry, outperforming 62.07% of the companies in the same industry.
  • A Quick Ratio of 4.02 indicates that CDXS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.02, CDXS is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 4.02
CDXS Yearly Current Assets VS Current LiabilitesCDXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.64% over the past year.
  • CDXS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.87%.
  • The Revenue has been decreasing by -2.83% on average over the past years.
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%

3.2 Future

  • CDXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.71% yearly.
  • Based on estimates for the next years, CDXS will show a quite strong growth in Revenue. The Revenue will grow by 19.17% on average per year.
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CDXS Yearly Revenue VS EstimatesCDXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
CDXS Yearly EPS VS EstimatesCDXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • CDXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CDXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDXS Price Earnings VS Forward Price EarningsCDXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDXS Per share dataCDXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CDXS's earnings are expected to grow with 21.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.37%
EPS Next 3Y21.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CDXS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CODEXIS INC

NASDAQ:CDXS (2/13/2026, 8:00:02 PM)

After market: 1.2 0 (0%)

1.2

+0.02 (+1.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners70.6%
Inst Owner Change1.4%
Ins Owners2.46%
Ins Owner Change2.12%
Market Cap108.38M
Revenue(TTM)52.93M
Net Income(TTM)-63.95M
Analysts81.54
Price Target6.71 (459.17%)
Short Float %6.76%
Short Ratio5.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.18%
Min EPS beat(2)-45.17%
Max EPS beat(2)16.81%
EPS beat(4)1
Avg EPS beat(4)-70.83%
Min EPS beat(4)-251.59%
Max EPS beat(4)16.81%
EPS beat(8)3
Avg EPS beat(8)-35.92%
EPS beat(12)5
Avg EPS beat(12)-23.74%
EPS beat(16)9
Avg EPS beat(16)-8.31%
Revenue beat(2)1
Avg Revenue beat(2)-23.96%
Min Revenue beat(2)-54.44%
Max Revenue beat(2)6.53%
Revenue beat(4)1
Avg Revenue beat(4)-23.66%
Min Revenue beat(4)-54.44%
Max Revenue beat(4)6.53%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)5
Avg Revenue beat(12)-3.57%
Revenue beat(16)8
Avg Revenue beat(16)-0.26%
PT rev (1m)0%
PT rev (3m)-1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)48.42%
EPS NY rev (1m)0%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B 2.81
P/tB 3
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.59
BVpS0.43
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.59%
ROE -165.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.32%
FCFM N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.25%
Cap/Sales 10.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 4.02
Altman-Z -6.8
F-Score3
WACC11.83%
ROIC/WACCN/A
Cap/Depr(3y)106.81%
Cap/Depr(5y)185.7%
Cap/Sales(3y)6.52%
Cap/Sales(5y)7.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%
EBIT growth 1Y-17.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.2%
EBIT Next 3Y12.55%
EBIT Next 5Y12.02%
FCF growth 1Y-48.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.46%
OCF growth 3YN/A
OCF growth 5YN/A

CODEXIS INC / CDXS FAQ

Can you provide the ChartMill fundamental rating for CODEXIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CDXS.


What is the valuation status for CDXS stock?

ChartMill assigns a valuation rating of 1 / 10 to CODEXIS INC (CDXS). This can be considered as Overvalued.


Can you provide the profitability details for CODEXIS INC?

CODEXIS INC (CDXS) has a profitability rating of 1 / 10.


Can you provide the financial health for CDXS stock?

The financial health rating of CODEXIS INC (CDXS) is 3 / 10.


Can you provide the expected EPS growth for CDXS stock?

The Earnings per Share (EPS) of CODEXIS INC (CDXS) is expected to grow by 25.65% in the next year.